IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Takeda will seek an external partner to leverage its cell therapy platform technologies
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Subscribe To Our Newsletter & Stay Updated
